Two-year phase 3 results show sustained visual benefit from aflibercept injection

Subjects who were injected with aflibercept for the treatment of diabetic macular edema showed a sustained improvement from baseline in best corrected visual acuity at week 100 compared with those who received laser photocoagulation, according to a press release from Regeneron. One hundred fifty-five patients in the randomized phase 3 VISTA-DME trial of Eylea (aflibercept, Regeneron) received 2 mg dosed monthly, 152 patients received 2 mg dosed every 2 months after five initial monthly injections, and 154 patients received laser photocoagulation.

Full Story →